Maze Therapeutics, Inc. (MAZE) Stock

Understand Maze Therapeutics, Inc.: how it makes money

Maze Therapeutics is a clinical stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, metabolic diseases, and obesity, including MZE829 (Phase II for APOL1 kidney disease) and MZE782 (Phase I for chronic kidney disease), and the provided latest-quarter financials show revenue of 0.0B.

With no provided product revenue, the profit model is structurally dependent on whether its kidney-focused clinical programs (MZE829 in Phase II and MZE782 in Phase I) generate enough efficacy signals, which in the provided data are tracked through urine albumin and proteinuria reduction measures.

Business quality (Weak): Clear biological and clinical focus on kidney disease with measurable urine-based efficacy endpoints, but the company is still early in development, operates with no provided revenue, and the provided cohort size metrics are small, increasing uncertainty around durability and broader patient impact.

Bull case

• MZE829 efficacy signals are measurable on urine albumin reduction endpoints in broad APOL1-mediated kidney disease, with a mean reduction of 36.0 percent and 50.0 percent of patients achieving at least a 30 percent reduction: These endpoints align with the program's stated kidney disease focus and provide trackable clinical progress while it is in Phase II.
• Additional patient efficacy metrics for related patient groups are also reported, including 61.8 percent mean reduction in urine albumin to creatinine ratio in FSGS patients: This suggests the program data, as provided, may be relevant beyond only one narrow subgroup.

Bear case

• The provided analyzed cohort size metrics are small, with 15 patients included in the analyzed cohort for Horizon and 12 patients evaluated for efficacy in Horizon: Small cohorts can limit how confidently results generalize to broader populations.
• The latest-quarter provided financials show revenue of 0.0B and an operating margin of -132.8 percent: This indicates heavy ongoing operating losses while the company remains clinical stage, increasing financing and development execution risk.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Recursion Pharmaceuticals, Inc. (RXRX)
• Taysha Gene Therapies, Inc. (TSHA)
• Vir Biotechnology, Inc. (VIR)
• Inhibrx Biosciences, Inc. (INBX)
• Novavax, Inc. (NVAX)
• Cullinan Therapeutics, Inc. (CGEM)
• Replimune Group, Inc. (REPL)
• Monte Rosa Therapeutics, Inc. (GLUE)